1. Home
  2. ATEN vs MLYS Comparison

ATEN vs MLYS Comparison

Compare ATEN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATEN
  • MLYS
  • Stock Information
  • Founded
  • ATEN 2004
  • MLYS 2019
  • Country
  • ATEN United States
  • MLYS United States
  • Employees
  • ATEN N/A
  • MLYS N/A
  • Industry
  • ATEN EDP Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATEN Technology
  • MLYS Health Care
  • Exchange
  • ATEN Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • ATEN 1.3B
  • MLYS 1.0B
  • IPO Year
  • ATEN 2014
  • MLYS 2023
  • Fundamental
  • Price
  • ATEN $18.25
  • MLYS $16.12
  • Analyst Decision
  • ATEN Buy
  • MLYS Strong Buy
  • Analyst Count
  • ATEN 2
  • MLYS 3
  • Target Price
  • ATEN $21.00
  • MLYS $33.00
  • AVG Volume (30 Days)
  • ATEN 707.3K
  • MLYS 801.2K
  • Earning Date
  • ATEN 07-29-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • ATEN 1.31%
  • MLYS N/A
  • EPS Growth
  • ATEN 9.85
  • MLYS N/A
  • EPS
  • ATEN 0.67
  • MLYS N/A
  • Revenue
  • ATEN $267,158,000.00
  • MLYS N/A
  • Revenue This Year
  • ATEN $9.40
  • MLYS N/A
  • Revenue Next Year
  • ATEN $7.66
  • MLYS N/A
  • P/E Ratio
  • ATEN $27.25
  • MLYS N/A
  • Revenue Growth
  • ATEN 4.90
  • MLYS N/A
  • 52 Week Low
  • ATEN $12.27
  • MLYS $8.24
  • 52 Week High
  • ATEN $21.90
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • ATEN 65.38
  • MLYS 57.84
  • Support Level
  • ATEN $17.52
  • MLYS $15.27
  • Resistance Level
  • ATEN $17.93
  • MLYS $16.43
  • Average True Range (ATR)
  • ATEN 0.33
  • MLYS 0.88
  • MACD
  • ATEN 0.06
  • MLYS -0.06
  • Stochastic Oscillator
  • ATEN 97.99
  • MLYS 63.81

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: